Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Rate of tumor response (neuroblastoma)

* as assessed by International Neuroblastoma Response * Primary tumor: CT and/or MRI; MIBG scan if available * Metastatic sites: bone marrow biopsies, CT/MRI, MIBG scan * CR (Complete response): No tumor (primary \& metastatic) * VGPR (Very good PR): Decreased by 90-99% (primary) \& no tumor (metastatic) * PR (Partial response): Decreased by \> 50% (primary \& metastatic) * MR (Mixed response): \> 50% reduction of any measurable lesion (primary or metastases) with \< 50% reduction in any other; \< 25% increase in any existing lesion * SD (Stable disease): No new lesions; \< 50% reduction but \< 25% increase in any existing lesion. * PD (Progressive disease): Any new lesion; increase of any measurable lesion by \> 25%

Time frame: 4 weeks

Rate of tumor response (brain tumor)

\- as assessed by 2-dimensional measurement (the product of the tumor's longest diameter and its longest perpendicular diameter) * CR: complete disappearance of all previously measurable tumors. * PR: greater than 50% decrease in tumor size * SD: less than 50% reduction in tumor size or less than 25% increase in tumor size * PD: greater than 25% increase in tumor size or the appearance of a new tumor

Time frame: 4 weeks

Rate of tumor response (other solid tumors)

\- as assessed by The Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) * CR: Disappearance of all target lesions. * PR: At least a 30% decrease in the sum of diameters of target lesions * SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD * PD: At least a 20% increase in the sum of diameters of target lesions